CLAIMS

1. A nucleic acid construct which comprises:

(1) a cDNA molecule encoding a full length antigenomic (+) RNA strand of a measles virus (MeV);

(2) a first heterologous polynucleotide encoding at least one polypeptide, or an antigenic fragment thereof, of a Lassa virus (LASV), said at least one polypeptide being selected from the group consisting of the nucleoprotein (NP), a mutated nucleoprotein (mNP), the glycoprotein precursor (GPC) and the zinc-binding protein (Z);

and wherein the first heterologous polynucleotide is operatively cloned within an additional transcription unit (ATU) inserted within the cDNA of the antigenomic (+) RNA, in particular an ATU localized between the P gene and the M gene of the MeV, in particular the ATU2 inserted between the P gene and the M gene of the MeV.

2. A nucleic acid construct according to claim 1 further comprising a second heterologous polynucleotide encoding at least one polypeptide, or an antigenic fragment thereof, of the LASV, said at least one polypeptide being selected from the group consisting of the GPC protein, the NP protein, the mNP protein and Z protein, the second heterologous polynucleotide being operatively cloned within another ATU at a location distinct from the location of the first cloned heterologous polynucleotide, preferentially upstream the N gene of the MeV, said another ATU being in particular the ATU1 inserted upstream the N gene of the MeV, the second heterologous polynucleotide encoding in particular at least one polypeptide or antigenic fragment thereof different from at least one polypeptide encoded by the first heterologous polynucleotide.

3. The nucleic acid construct according to claim 1 or 2, wherein the heterologous polynucleotide(s) encoding the GPC protein, the NP protein, the mNP and/or the Z protein, or an antigenic fragment thereof, is(are) from the LASV strain *Josiah*, or is(are) derived from the LASV

strain *Josiah*, in particular the heterologous polynucleotide(s) is(are) issued or derived from the sequence of Genbank J04324.1 and/or U73034.2.

4. The nucleic acid construct according to any one of claims 1 to 3, wherein the first and/or second heterologous polynucleotide(s) encode(s) the mNP protein, or an antigenic fragment thereof , wherein the mNP protein has a mutated exonuclease domain, in particular wherein the amino acid sequence of the encoded mNP protein is mutated on amino acid residue 389 and/or 392, preferentially by substitution on amino acid residues 389 and 392, of SEQ ID No: 3, in particular the encoded mNP protein is the sequence of SEQ ID No: 5, in particular the heterologous polynucleotide encoding the mNP protein comprises SEQ ID No: 6.

5. The nucleic acid construct according to any one of claims 1 to 4, wherein the heterologous polynucleotide(s) encoding the GPC protein, the NP protein, the mNP protein and/or the Z protein, or an antigenic fragment thereof, has (have) codon-optimized open reading frame(s) (ORF), in particular, the heterologous polynucleotide(s) comprise(s) at least one of the following sequence:
   - SEQ ID No: 2 which encodes the GPC protein; and/or
   - SEQ ID No: 4 which encodes the NP protein; and/or
   - SEQ ID No: 6 which encodes the mNP protein; and/or
   - SEQ ID No: 8 which encodes the Z protein.

6. The nucleic acid construct according to any one of claims 1 to 5, wherein the heterologous polynucleotide(s) encode(s):
   - the GPC protein of SEQ ID No: 1 or an antigenic fragment thereof; and/or
   - the NP protein of SEQ ID No: 3 or an antigenic fragment thereof; and/or
   - the mNP protein of SEQ ID No: 5 or an antigenic fragment thereof; and/or

- the Z protein of SEQ ID No: 7 or an antigenic fragment thereof.

7. The nucleic acid construct according to any one of claims 1 to 6 comprising from 5' to 3' end the following polynucleotides:
(a) a polynucleotide encoding the N protein of the MeV;
(b) a polynucleotide encoding the P protein of the MeV;
(c) the first heterologous polynucleotide encoding at least one polypeptide selected from the group consisting of the GPC protein, the NP protein, the mNP protein and the Z protein of the LASV, or an antigenic fragment thereof, in particular encoding a single polypeptide which is the GPC protein or an antigenic fragment thereof, or encoding at least two polypeptides, which are the GPC protein or an antigenic fragment thereof and either the NP protein or the mNP protein, or an antigenic fragment thereof, in particular encoding the GPC protein and the mNP protein, wherein the first polynucleotide is in particular operatively cloned within an ATU, in particular ATU2;
(d) a polynucleotide encoding the M protein of the MeV;
(e) a polynucleotide encoding the F protein of the MeV;
(f) a polynucleotide encoding the H protein of the MeV;
(g) a polynucleotide encoding the L protein of the MeV;
and wherein said polynucleotides are operatively linked within the nucleic acid construct and under the control of a viral replication and transcriptional regulatory elements such as MeV leader and trailer sequence(s).

8. The nucleic acid construct according to any one of claims 2 to 6 comprising from 5' to 3' end the following polynucleotides:
(a) the second heterologous polynucleotide encoding at least one polypeptide selected from the group consisting of the GPC protein, the NP protein, the mNP protein and the Z protein of the LASV, or an antigenic fragment thereof, in particular encoding the Z protein, or an antigenic fragment thereof, wherein the second polynucleotide is

operatively cloned within an ATU localized upstream the N gene of the MeV, in particular within the ATU1;

(b) a polynucleotide encoding the N protein of the MeV;

(c) a polynucleotide encoding the P protein of the MeV;

(d) the first heterologous polynucleotide encoding at least one polypeptide selected from the group consisting of the GPC protein, the NP protein, the mNP protein and the Z protein of the LASV, or an antigenic fragment thereof, in particular encoding a single polypeptide which is the GPC protein or an antigenic fragment thereof, or encoding at least two polypeptides, which are the GPC protein or an antigenic fragment thereof and either the NP protein or the mNP protein, or an antigenic fragment thereof, in particular encoding the GPC protein and the mNP protein, wherein the first polynucleotide is in particular operatively cloned within an ATU, in particular ATU2;

(e) a polynucleotide encoding the M protein of the MeV;

(f) a polynucleotide encoding the F protein of the MeV;

(g) a polynucleotide encoding the H protein of the MeV;

(h) a polynucleotide encoding the L protein of the MeV,

and wherein said polynucleotides are operatively linked within the nucleic acid construct and under the control of a viral replication and transcriptional regulatory elements such as MeV leader and trailer sequence(s).

9. The nucleic acid construct according to any one of claims 1 to 8, wherein the first heterologous polynucleotide comprises from 5' to 3' end:

(a) a nucleic acid encoding the NP protein or the mNP protein of the LASV, or an antigenic fragment thereof, in particular whose nucleic acid is SEQ ID No: 4 for the NP protein or SEQ ID No: 6 for the mNP protein; and

(b) a nucleic acid encoding the GPC protein of the LASV, or an antigenic fragment thereof, in particular whose nucleic acid is SEQ ID No: 2;

and wherein the first heterologous polynucleotide is operatively cloned between the P gene and the M gene of the MeV, in particular within an ATU, in particular ATU2.

10. The nucleic acid construct according to any one of claims 1 to 9, wherein the first heterologous polynucleotide comprises from 5' to 3' end:
(a) the nucleic acid of SEQ ID No: 6 encoding the mNP protein; and
(b) the nucleic acid of SEQ ID No: 2 encoding the GPC protein;
and wherein the first heterologous polynucleotide sequence is operatively cloned between the gene P and the gene M of the MeV, in particular within an ATU, in particular ATU2.

11. The nucleic acid construct according to any one of claims 2 to 10, wherein the second heterologous polynucleotide encodes the Z protein of the LASV, or an antigenic fragment thereof, and wherein the first heterologous polynucleotide encodes the GPC protein of the LASV, or an antigenic fragment thereof, in particular wherein the sequence of the second heterologous polynucleotide comprises the sequence of SEQ ID No: 8 and the sequence of the first heterologous polynucleotide comprises the sequence of SEQ ID No: 2.

12. The nucleic acid construct according to claim 11, wherein the first heterologous polynucleotide and the second heterologous polynucleotide are operatively cloned within ATUs located at different position in the cDNA molecule of the MeV, in particular the first heterologous polynucleotide is operatively cloned with the ATU2 and the second heterologous polynucleotide is operatively cloned within the ATU1.

13. The nucleic acid construct according to any one of claims 1 to 12, wherein the measles virus is an attenuated virus strain selected from the group consisting of the Schwarz strain, the Zagreb strain, the AIK-C strain, the Moraten strain, the Philips strain, the Beckenham 4A strain, the Beckenham 16 strain, the Edmonston seed A strain, the Edmonston

seed B strain, the CAM-70 strain, the TD 97 strain, the Leningrad-16 strain, the Shanghai 191 strain and the Belgrade strain, in particular the Schwarz strain.

14. The nucleic acid construct according to any one of claims 1 to 13, wherein the sequence of the first heterologous polynucleotide comprises at least one of SEQ ID No: 2, SEQ ID No: 4, SEQ ID No: 6, and/or SEQ ID No: 8, and preferentially at least SEQ ID No: 2, in particular SEQ ID No: 2 and SEQ ID No: 6.

15. The nucleic acid construct according to any one of claims 1 to 14 whose recombinant cDNA sequence is selected from the group consisting of:
- SEQ ID No: 9 (construct MeV-GPC);
- SEQ ID No: 10 (construct MeV-NP-GPC);
- SEQ ID No: 11 (construct MeV-mNP-GPC);
- SED ID No: 12 (construct Z-MeV-GPC);
- SEQ ID No: 13 (construct Z-MeV-NP-GPC); and
- SEQ ID No: 14 (construct Z-MeV-mNP-GPC).

16. A transfer plasmid vector comprising the nucleic acid construct according to any one of claims 1 to 15, in particular comprising or consisting of a sequence selected from the group consisting of:
- SEQ ID No: 9 (Plasm MeV-GPC);
- SEQ ID No: 10 (Plasm MeV-NP-GPC);
- SEQ ID No: 11 (Plasm MeV-mNP-GPC);
- SED ID No: 12 (Plasm Z-MeV-GPC);
- SEQ ID No: 13 (Plasm Z-MeV-NP-GPC); and
- SEQ ID No: 14 (Plasm Z-MeV-mNP-GPC).

17. A recombinant measles virus, said virus comprising in its genome a nucleic acid construct according to any one of claims 1 to 15, or a transfer plasmid vector according to claim 16, or whose genome consists of the transfer plasmid vector of claim 16.

18. The recombinant measles virus according to claim 17 expressing at least one polypeptide selected from the group consisting of the GPC protein, the NP protein, the mNP protein and the Z protein of the LASV, or an antigenic fragment thereof, in particular expressing at least two polypeptide selected from the group consisting of the GPC protein, the NP protein, the mNP protein and the Z protein of the LASV, or an antigenic fragment thereof.

19. The recombinant measles virus according to claim 17 or 18 expressing the GPC protein and the mNP protein of the LASV, or antigenic fragments thereof.

20. The recombinant measles virus according to claim 17 or 18 expressing the GPC protein and the Z protein of the LASV, or antigenic fragments thereof.

21. The recombinant measles virus according to any one of claims 17 to 20 furthermore expressing at least one of the N protein, the P protein, the M protein, the F protein, the H protein and the L protein of the MeV.

22. The recombinant measles virus according to any one of claims 17 to 21, which elicits a cellular and/or humoral and cellular response, in particular after a single immunization, against the antigenic fragment(s) of the GPC protein, the NP protein, the mNP protein and/or the Z protein of LASV, in particular against the antigenic fragments of the N protein, the P protein, the M protein, the F protein, the H protein and/or the L protein of MeV, in particular a T cell response, in particular a CD4+ and CD8+ T cell response.

23. A host cell transfected with the nucleic acid construct according to any one of claims 1 to 15 or with the transfer plasmid vector according to claim 16, or infected with the recombinant measles virus according to any one of claims 17 to 22, in particular a mammalian cell, a VERO NK cells, CEF cells, human embryonic kidney cell line 293 or MRC5 cells.

24. Recombinant virus like particles (VLPs) comprising a Z protein and optionally a GPC protein and/or a NP protein and/or a mNP protein, or an antigenic fragment thereof, of the LASV, in particular expressing at least the Z protein and the GPC protein, or an antigenic fragment thereof, wherein the protein(s) or antigenic fragments thereof is(are) encoded by the first and/or second heterologous polynucleotide(s) of the nucleic acid construct according to claims 1 to 15, or of the transfer plasmid vector of claim 16, or the recombinant measles virus according to any one of claims 17 to 22, or produced within the host cell of claim 23.

25. An immunogenic composition, especially a virus vaccine composition, comprising the recombinant VLPs according to claim 24, or the recombinant measles virus according to any one of claims 17 to 22, or the recombinant VLPs according to claim 24 and the recombinant measles virus according to any one of claims 17 to 22, and a pharmaceutically acceptable vehicle.

26. The composition according to claim 25 for use in the elicitation of a protective, and preferentially prophylactic, immune response against the Lassa virus by the elicitation of antibodies directed against LASV protein(s) or antigenic fragment(s) thereof, and/or a cellular and/or humoral and cellular response against the Lassa virus, in a host in need thereof, in particular a human host, in particular a child.

27. The composition of claim 26 for use in the elicitation of a protective, and preferentially prophylactic, immune response against measles virus by the elicitation of antibodies directed against measles virus protein(s), and/or a cellular and/or humoral and cellular response against the measles virus, in a host in need thereof, in particular a human host, in particular a child.

28. A process for rescuing recombinant Lassa virus like particles (VLPs) and/or recombinant measles virus expressing at least one of polypeptide

selected from the group consisting of the GPC protein, the NP protein, the mNP protein and the Z protein of LASV, or an antigenic fragment thereof, comprising:

(a) transfecting cells, in particular helper cells, in particular HEK293 helper cells, stably expressing T7 RNA polymerase and measles virus N and P proteins with the nucleic acid construct according to any one of claims 1 to 15 or with the transfer plasmid vector according to claim 16;

(b) maintaining the transfected cells in conditions suitable for the production of recombinant measles virus and/or LASV VLPs;

(c) infecting cells enabling propagation of the recombinant measles virus and/or the LASV VLPs by co-cultivating them with the transfected cells of step (b);

(d) harvesting the recombinant measles virus expressing at least one of the GPC protein, the NP protein, the mNP protein and/or the Z protein of LASV, in particular expressing at least the GPC protein and another LASV protein, in particular expressing the GPC protein and the mNP protein, and/or the LASV VLPs expressing at least the Z protein and optionally at least one of the GPC protein, the NP protein and/or the mNP protein of LASV, in particular expressing the Z protein and the GPC protein.

29. A method for preventing a Lassa virus related disease, said method comprising the immunization of a mammalian, especially a human, in particular a child, by the injection, in particular by subcutaneous injection, of recombinant Lassa virus VLPs according to claim 24, and/or a measles virus according to any one of claims 17 to 22.

30. A method for treating a Lassa virus related disease, said method comprising the immunization of a mammalian, especially a human, in particular a child, by the injection, in particular subcutaneous injection, of recombinant Lassa virus VLPs according to claim 24, and/or a measles virus according to any one of claims 17 to 22.